Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
CABAZITAXEL-TEVA (Teva Pharma Australia Pty Ltd)
Product name
CABAZITAXEL-TEVA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
253 working days (255)
Active ingredients
cabazitaxel ethyl acetate solvate
Registration type
New generic medicine
Indication
CABAZITAXEL-TEVA (concentrated solution for injection) in combination with prednisone or prednisolone is indicated for the treatment of patients with metastatic castration resistant prostate cancer previously treated with a docetaxel containing regimen.